Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Eyes and Vision

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 50%High 2 · 50%

Summary of findings 1: Efficacy and safety of IVT lampalizumab 4‐weekly (monthly) vs sham

Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with GA due to AMD

1 finding from 1 review

Complement inhibitors for age‐related macular degeneration 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1182 participants
High

Summary of findings 3: Efficacy and safety of IVT pegcetacoplan 4‐weekly (monthly) vs sham

Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with GA due to AMD

1 finding from 1 review

Complement inhibitors for age‐related macular degeneration 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 164 participants
Moderate

Summary of findings 4: Efficacy and safety of IVT pegcetacoplan 8‐weekly (every other month) vs sham

Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with GA due to AMD

Summary of findings 4: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in change in BCVA from baseline at 1 year (ETDRS letters) compared with sham (moderate certainty).

1 finding from 1 review

Complement inhibitors for age‐related macular degeneration 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 158 participants
Moderate

Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to 8‐weekly (every other month) vs sham

Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with GA due to AMD

1 finding from 1 review

Complement inhibitors for age‐related macular degeneration 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1184 participants
High